巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Amgen

    AMGN
    244.800
    0.520
    0.21%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Amgen - 延遲價格・最後更新於 18/05 6:46
    最高位
    247.310
    最低位
    244.200
    開市價
    --
    前收市價
    245.320
    成交量(千)
    128.17
    成交額(百萬)
    280.96
    買入
    244.670
    賣出
    244.910
    每手股數
    --
    市值(百萬)
    130,772.14
    市盈率
    24.170
    息率
    3.03%
    差價
    --
    52週高低
    258.450 - 198.640
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Amgen
    證券代碼
    AMGN.US
    所屬板塊
    Drug Manufacturers - General
    公司業務
    Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
    發行量
    557029370
    公司總部
    One Amgen Center Drive
    公司網址
    https://www.amgen.com
    公司電郵
    investor.relations@amgen.com
    公司電話
    +1 805 447-1000

    美股異動丨安進(AMGN.US)盤前跌逾5% 或將向美國國税局補繳共計71億美元税款和罰款

    格隆匯·
    美股異動丨安進(AMGN.US)盤前跌逾5% 或將向美國國税局補繳共計71億美元税款和罰款

    美股異動丨安進(AMGN.US)盤前跌逾5% 或將向美國國税局補繳共計71億美元税款和罰款

    格隆匯·
    美股異動丨安進(AMGN.US)盤前跌逾5% 或將向美國國税局補繳共計71億美元税款和罰款

    安進(AMGN.US)漲6.7%,去年四季度淨利同比增18%

    格隆匯·
    安進(AMGN.US)漲6.7%,去年四季度淨利同比增18%

    安進(AMGN.US)漲6.7%,去年四季度淨利同比增18%

    格隆匯·
    安進(AMGN.US)漲6.7%,去年四季度淨利同比增18%

    百濟神州擬於科創板發行1.15億股A股

    張偉倫·
    百濟神州擬於科創板發行1.15億股A股

    關於

    Amgen(AMGN.US)所屬的行業板塊為Drug Manufacturers - General。
    Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
    截至18/05 06:46:07,Amgen的股價跌-0.21,市值130,772.14百萬。Amgen的市盈率及息率分別為24.170及3.03%。
    詳細公司背景可參考: https://www.amgen.com